Navigation Links
NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder
Date:12/2/2008

PRINCETON, N.J., Dec. 2 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp., a developer and manufacturer of medical products that fight infection and inflammation, announced today that its Board of Directors has received from its majority shareholder, The Westaim Corporation ("Westaim"), a requisition to call a special meeting of shareholders to consider a return of capital of US$0.80 per share to NUCRYST shareholders. This equates to a return of capital of approximately US$15 million. The special meeting requisition also requests that shareholders set the number of directors of NUCRYST and elect directors.

A Special Committee of the NUCRYST Board comprised of non-conflicted directors has been formed to oversee the process of calling the special meeting and to provide advice and recommendations to the NUCRYST Board as may be required. BMO Capital Markets has been retained as financial advisor to the Special Committee and McMillan LLP of Toronto has been retained to provide the Special Committee with independent legal advice. Until NUCRYST completes its review, NUCRYST will not further comment on the special meeting requisition.

About NUCRYST Pharmaceuticals

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care coating products to Smith & Nephew plc, which markets these products in over 30 countries under their Acticoat(TM) trademark. NUCRYST is also developing pharmaceutical products to address medical conditions that are characterized by pain, infection and inflammation. The Company has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101 for use in medical devices and as an active pharmaceutical ingredient.

    Acticoat(TM) is a trademark of Smith & Nephew plc
    SILCRYST(TM) is a trademark of NUCRYST Pharmaceuticals Corp.

This news release contains forward-looking statements within the meaning of securities legislation in the United States and Canada (collectively "forward-looking statements"). Forward-looking statements in this news release include, but are not limited to, statements about our plans to review and respond to the special meeting requisition. With respect to the forward-looking statements contained in this news release, readers are cautioned that numerous risks, uncertainties and other factors could cause our actual results to differ materially from those indicated in these statements including, but not limited to: Westaim's stated intention to review its alternatives for maximizing the value of its stake in NUCRYST, the identification and pursuit of new opportunities to grow the value of NUCRYST; performance of stock markets generally; our ability to satisfy regulatory and stock exchange standards and requirements to maintain our exchange listing; our future operation results are uncertain and likely to fluctuate; our ability to maintain our collaboration with Smith & Nephew; our reliance on sales of Acticoat(TM) products with our SILCRYST(TM) coatings by Smith & Nephew; and the future financial performance and operating performance of Smith & Nephew. Although we have attempted to identify the important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in forward-looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in forward looking statements. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our Annual Report on Form 10-K for the year ended December 31, 2007 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov and with securities authorities in Canada on SEDAR at www.sedar.com. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and NUCRYST disclaims any intention or obligation to revise or update any forward-looking statements whether as a result of new information, future developments or otherwise after the date hereof.


'/>"/>
SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
2. NUCRYST Receives Deficiency Notice from NASDAQ
3. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
4. NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer
5. NUCRYST Announces First Quarter 2008 Financial Results
6. NUCRYST Announces Management Realignment and R&D Portfolio Change
7. NUCRYST Announces Senior Management Change
8. NUCRYST Pharmaceuticals announces year-end results
9. NUCRYST Pharmaceuticals announces 2007 third quarter results
10. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
11. NUCRYST and Smith & Nephew Revise Agreements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Mental health watchdog Citizens Commission on ... and renowned professor of psychiatry Thomas Szasz, is continuing its protest against the use ... Death” exhibit in Atlanta, Georgia. The opening of the exhibit follows CCHR’s recent protest ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Loma Linda University ... new adult hospital and expanded Children’s Hospital. Over 3,000 people looked on as the ... Check out the event photo slidehsow. , During the program, Richard H. Hart, ...
(Date:5/24/2016)... ... , ... Backed by decades of experience, Metroloji Okulu works ... best suited solution to meet regulatory requirements. Their professional staff also performs on-site ... , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical data ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Growing in ... growing trend, more gluten-free products are available and easily accessible. Whether someone chooses to ... to cater to a certain diet, King Kullen Grocery stocks their shelves with many ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... by 9.3 million people, or 10% over last year, according to data in ... under group policies was comparatively stable, with a slight decrease in risk-based groups ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
(Date:5/23/2016)... -- Non-invasive diagnostic test realizes the potential ... to be presented at Yissum’s booth, at IATI-BIOMED 2016 ... of the Hebrew University of Jerusalem announced today ... Ventures MKI, the technology investment arm of Morris Kahn ... for early detection of multiple diseases by analyzing circulating ...
(Date:5/23/2016)... 2016   Purdue Pharma L.P.  today announced ... with Egalet Corporation and Acura Pharmaceuticals, Inc. that ... the agreement the companies will exchange valuable patent ... companies to develop and sell several opioid pain ... reflects the commitment of Purdue Pharma to seek ...
Breaking Medicine Technology: